Results 91 to 100 of about 21,836 (300)
Current Opinion in Infectious Diseases, 2014 Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications.Echinocandin resistance has emerged over the ...
Maiken Cavling Arendrup, David S. Perlin
openaire +3 more sources
iLABMED, Volume 3, Issue 3, Page 258-262, September 2025.ABSTRACT This paper reports a case of Chlamydia psittaci pneumonia and pulmonary aspergillosis with concurrent liver injury. The patient was admitted to the hospital with coughing, expectoration, and fever for 5 days. Laboratory tests upon admission revealed abnormalities in liver function.
Chang Song +5 more
wiley +1 more source
Тазовая хирургия и онкология, 2019 This review focuses on the practical aspects of prevention and treatment of fungal infections in surgical patients. It covers epidemiology and risk factors for invasive candidiasis, updates on the etiological structure of fungal infections in patients in
B. Z. Belotserkovskiy +4 more
doaj +1 more source
De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients with Candidemia
International Journal of Infectious Diseases, 2022 Objectives: This study aims to further explore the duration of echinocandins and analyze the de-escalation (DE) strategy in patients with candidemia. Methods: Multivariable logistic regression was used to evaluate the association between the duration of ...
Jing Lin +5 more
doaj +1 more source
Candida glabrata Resistance to Echinocandins Associated with FKS Genes Mutations: How Urgent is the Problem? [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2016 The resistance of the systemic Candida infections causative agents is a cornerstone of the selection of an effective therapy. But if before the problem was limited to resistance to azole antifungals, then by now we have enough data about cases of ...
Veselov A.V.
doaj
Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science, Volume 18, Issue 9, September 2025.ABSTRACT Ibrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal pediatric females.
Adelynne H. Walley +3 more
wiley +1 more source
Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010–16 [PDF]
, 2019 Background The need for antifungal stewardship is gaining recognition with increasing incidence of invasive fungal infection (IFI) and antifungal resistance alongside the high cost of antifungal drugs.
Al-Ghusein, H +9 more
core +1 more source
Metabolites, 2020 We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein ...
Jiří Houšť +2 more
doaj +1 more source
Mycoses, Volume 68, Issue 9, September 2025.ABSTRACT Background Starting from 2018 onwards, several outbreaks of fluconazole‐resistant C. parapsilosis have been reported in many countries worldwide. Objectives Here we report a retrospective study on C. parapsilosis blood isolates collected over 7 years (2018–2024) in two hospitals in Northern Italy.
Giorgia Palladini +12 more
wiley +1 more source
Sentinel Case of Candida auris in the Western United States Following Prolonged Occult Colonization in a Returned Traveler from India. [PDF]
, 2019 Candida auris is an emerging multidrug-resistant yeast with high mortality. We report the sentinel C. auris case on the United States West Coast in a patient who relocated from India.
Crawford, Emily D +12 more
core +1 more source